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A B S T R A C T
Background
Rotavirus, predominantly of group A, is a major cause of severe diarrhoea worldwide, with
the greatest burden falling on young children living in less-developed countries. Vaccines
directed against this virus have shown promise in recent trials, and are undergoing
effectiveness evaluation in sub-Saharan Africa. In this region limited childhood data are
available on the incidence and clinical characteristics of severe group A rotavirus disease.
Advocacy for vaccine intervention and interpretation of effectiveness following implementa-
tion will benefit from accurate base-line estimates of the incidence and severity of rotavirus
paediatric admissions in relevant populations. The study objective was to accurately define the
incidence and severity of group A rotavirus disease in a resource-poor setting necessary to
make informed decisions on the need for vaccine prevention.
Methods and Findings
Between 2002 and 2004 we conducted prospective surveillance for group A rotavirus
infection at Kilifi District Hospital in coastal Kenya. Children , 13 y of age were eligible as
‘‘cases’’ if admitted with diarrhoea, and ‘‘controls’’ if admitted without diarrhoea. We calculated
the incidence of hospital admission with group A rotavirus using data from a demographic
surveillance study of 220,000 people in Kilifi District. Of 15,347 childhood admissions 3,296
(22%) had diarrhoea, 2,039 were tested for group A rotavirus antigen and, of these, 588 (29%)
were positive. 372 (63%) rotavirus-positive cases were infants. Of 620 controls 19 (3.1%, 95%
confidence interval [CI] 1.9–4.7) were rotavirus positive. The annual incidence (per 100,000
children) of rotavirus-positive admissions was 1,431 (95% CI 1,275–1,600) in infants and 478
(437–521) in under-5-y-olds, and highest proximal to the hospital. Compared to children with
rotavirus-negative diarrhoea, rotavirus-positive cases were less likely to have coexisting
illnesses and more likely to have acidosis (46% versus 17%) and severe electrolyte imbalance
except hyponatraemia. In-hospital case fatality was 2% among rotavirus-positive and 9%
among rotavirus-negative children.
Conclusions
In Kilifi . 2% of children are admitted to hospital with group A rotavirus diarrhoea in the first
5 y of life. This translates into over 28,000 vaccine-preventable hospitalisations per year across
Kenya, and is likely to be a considerable underestimate. Group A rotavirus diarrhoea is
associated with acute life-threatening metabolic derangement in otherwise healthy children.
Although mortality is low in this clinical research setting this may not be generally true in
African hospitals lacking rapid and appropriate management.
The Editors’ Summary of this article follows the references.
PLoS Medicine | www.plosmedicine.org July 2008 | Volume 5 | Issue 7 | e1531154
PLoSMEDICINE
Introduction
Rotavirus is a major cause of severe diarrhoea worldwide
causing in excess of 2 million hospitalisations per annum in
under-5-y-old children [1], and group A rotavirus (GARV) is
responsible for the vast majority of this disease [2]. In terms
of both morbidity and mortality, the greatest burden of
GARV diarrhoea falls on young children living in less-
developed countries [1,3], with Africa only second behind
the Indian subcontinent in suffering the major disease impact
[1]. Two vaccines directed against this virus have been shown
to be safe and highly effective [4,5], and trials of effectiveness
are now in progress in sub-Saharan Africa. Evidence-based
decisions regarding the wide-scale use of rotavirus vaccine
intervention will beneﬁt from accurate baseline estimates of
the incidence and clinical characteristics of GARV in
representative target populations [6,7].
Considerable effort has been expended in deﬁning the
burden of GARV-associated diarrhoeal disease burden in
Africa. A recent review of data from 14 countries within the
region reported a median prevalence of GARV in children
admitted to hospitals with diarrhoea of 24% (range 13%–
55%), 81% in children , 12 mo of age [8]. In Kenya, GARV
has been identiﬁed in 14%–39% of hospital diarrhoea cases
[9–11]. More recently rotavirus surveillance has intensiﬁed
through the support of the African Rotavirus Network [12]
and Rotavirus Vaccine Program [13]. Nevertheless, there is a
remarkable paucity of data on GARV incidence where the
population from which the patients arise is demographically
well deﬁned. Furthermore, the clinical spectrum of GARV
presentations is not well characterised. Accurate incidence
estimation and clear case deﬁnitions are vital components for
the evaluation of vaccine trial planning and programme
evaluation. The objectives of this study were to deﬁne these
components among paediatric inpatients in Kiliﬁ.
Methods
Study Location and Population
The study was conducted at Kiliﬁ District Hospital (KDH)
in a rural area on the coast of Kenya. The population of Kiliﬁ
District are predominantly subsistence farmers of the
Mgiriama tribe. Malaria transmission occurs in this area
throughout the year, with peaks in November–January and
May–August following seasonal rains. The paediatric wards at
KDH include a 36-bed general ward and a six-bed high-
dependency unit, which together admit over 5,000 children
each year. A standardized clinical history, examination, and
routine set of investigations (haematology, malaria parasite
microscopy, and blood culture) are conducted on all admitted
children [14–17] and the data entered directly into a
computer database. Further investigations, including blood
gas and biochemical analysis, are undertaken at the discretion
of the admitting clinician and dependent on the needs of
research studies in progress.
Since 2000 a demographic surveillance system (DSS) has
followed a population of approximately 220,000 individuals
residing in the area close to KDH [18]. The DSS area
encompasses 891 km2 and includes 15 administrative loca-
tions, which are further divided into 40 sublocations (Figure
1). This area included the residences of 80% of children
admitted to KDH in the period 1998–2000. Every household
was mapped and censused in 2000–2001 and was re-
enumerated at subsequent visits; in total there have been
ten enumeration rounds to-date, six occurring during the
present 3 y study. A resident was deﬁned as an individual who
lives (sleeps more than 50% of nights) in the identiﬁed
homestead or who intends to live there for a period of  3 mo
and has already spent at least one night there. Births, deaths,
and in- and out-migration events are recorded at re-
enumeration visits; births and deaths among children are
also recorded at the maternity department, vaccine clinic,
and wards of KDH. All sources of demographic data are
uploaded within 48 h to an integrated database system. From
16 April 2002 we have attempted to match each child
admitted to KDH paediatric ward to the register of DSS
residents to create accurate correspondence between numer-
ator and denominator data for incidence estimates.
Rotavirus Surveillance
All children aged , 13 y admitted to the wards of KDH
with a history of diarrhoea between 01 January 2002 and 31
December 2004 were eligible for inclusion in the study. These
children are termed ‘‘cases.’’ Diarrhoea was deﬁned as passing
three or more loose stools during the preceding 24 h. To
estimate the prevalence of GARV infection in the absence of
diarrhoeal disease we studied a group of children who were
admitted to the ward but who did not have a history of
diarrhoea; these patients are termed ‘‘controls’’ in the study.
Controls were contemporaneous to cases, randomly selected
in a ratio of one control to each three cases of diarrhoea, with
frequency matching to diarrhoea cases by age class. Stool
samples were collected as soon as possible after completion of
the recruitment process. To prevent possible confusion from
nosocomial transmission, diarrhoea cases and nondiarrhoea
controls became ineligible for recruitment 24 h after
admission.
HIV diagnostic counselling and testing were not estab-
lished in the wards at the time of this study and approval was
not sought to determine the HIV status of the study patients.
Written informed consent was obtained from the parent or
caretaker of each participant. Ethical approval was granted
for the study by the Kenyan National Research Ethical
Committee and by the Coventry Research Ethics Committee,
UK.
Laboratory Analysis
Stool samples were stored at80 8C until shipment on dry
ice for screening at the MRC Diarrhoeal Pathogens Research
Unit, South Africa. GARV antigen testing was conducted
using an enzyme immunoassay (IDEIA Rotavirus, DakoCyto-
mation) according to the manufacturers instructions. GARV-
positive samples from controls were tested for viral genome
pattern by PAGE as described previously [19].
Data Analysis
Analyses were performed by use of STATA v8.2 (Stata-
Corp). Incidence was deﬁned as the number, among residents,
of cases per 100,000 person-years of observation within age
and location strata, with Poisson-based 95% conﬁdence
intervals (CIs). Person-years of observation were deﬁned as
the midstudy resident population multiplied by the number
of years of linked surveillance (2.71 y, i.e., 16 April 2002 to 31
December 2004). The resident population of the DSS at the
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midpoint of the study (24 August 2003) was interpolated from
the linear equation determined by regressing population size
(log10) for all ten enumeration rounds against the mid-date of
each round. The midstudy population size for a sublocation
was estimated as the midpoint resident population weighted
by the fraction of individuals within that sublocation at the
enumeration round with mid-date 30 May 2003. A subloca-
tion was deﬁned as near to the district hospital if part of its
boundary fell within a circle of 5 km radius with KDH at its
centre. The population of resident under-5-y-olds within this
area represented 42% of the total in the DSS, and accounted
for 43% of all resident diarrhoea admissions. Among patients
with diarrhoea we examined the association between rotavi-
rus infection and a range of clinical signs and symptoms, and
coexisting illnesses. We deﬁned severe malnutrition using a
combination of mid-upper arm circumference (MUAC),
visible severe wasting, and bipedal oedema [20]. The diagnosis
of severe pneumonia, very severe pneumonia, and shock
followed modiﬁed WHO deﬁnitions [21,22]. Further catego-
risations on the basis of clinical and laboratory ﬁndings were
as described previously [23,24]. Proportions were compared
using the Fisher exact test (two-tailed) with exact 95% CIs and
Figure 1. Map of Kilifi Demographic Surveillance System (DSS), Showing the Under-5-Year-Old Incidence (Per 100,000 Per Year) by Sublocation of GARV-
Positive Diarrhoea Admissions to Kilifi District Hospital (H), 2002–2004
Sublocation data was pooled with nearest neighbour data where diarrhoea admissions in children under 5 y was less than 20 cases over the period of
surveillance. (Using DSS data from Figure 2 of reference [34].)
doi:10.1371/journal.pmed.0050153.g001
PLoS Medicine | www.plosmedicine.org July 2008 | Volume 5 | Issue 7 | e1531156
Group A Rotavirus in Kenyan Children
equality of distributions evaluated using the Wilcoxon rank-
sum test. Adjusted odds ratios (ORs) were determined using
logistic regression.
Results
Over the 3-y period 15,347 children aged , 13 y of age
were admitted to KDH. There were 3,296 diarrhoea cases with
a median age of 13 mo (interquartile range [IQR] 8–23 mo);
1,397 (42%) were female. For 35% (1,145) of cases a stool
sample was not collected, for the reasons detailed in Figure 2,
with the most important being a failure to provide a sample
within the 24 h time limit postadmission. Relative to those
who did provide a stool specimen, those who did not were
more likely to be admitted directly to the high-dependency
ward (15% versus 4%, p , 0.001) and to die before discharge
(13% versus 7%, p , 0.001). One hundred twelve diarrhoea
cases who provided a stool sample had no GARV test results.
An analysis of the possible bias upon rotavirus incidence and
severity characteristics from omission of the 1,257 eligible
cases who were not GARV tested, provided evidence that the
inﬂuence was not substantial (see Table S1 and Text S1).
There were 12,051 patients admitted without diarrhoea, of
whom 1,067 were selected as controls. The median age of the
control group was 11 mo (IQR 4–22 mo); 455 (43%) were
female. Reasons for failure to collect a stool sample from
controls were in similar proportions to cases (Figure 2). The
severity differential in sampled and nonsampled controls was
also similar to that of cases. Among children tested for GARV
antigen in the diarrhoea and control groups, the age (median
12.5 versus 12.2 mo, p ¼ 0.219) and sex (proportion female
43% versus 42%, p ¼ 0.926) distributions were very similar.
GARV-Associated Diarrhoea: Seasonality and Age
Distribution
Twenty-nine percent (588/2,039) of stool samples tested
positive for GARV antigen (Table 1). This proportion did not
vary signiﬁcantly by calendar year (p ¼ 0.686) or by sex (p ¼
0.199). Variation in the monthly GARV-positive cases mir-
rored approximately the pattern of diarrhoea admissions but
had no clear seasonal pattern or obvious association with
weather indicators (see Figure S1). Of all diarrhoea cases 83%
were aged 3–17 mo (Table 2) and the proportion of cases
GARV positive was higher in this age group (37%) than among
other children (14%). While 19% of cases under 3 mo old were
GARV positive, only 3% of all GARV positives were found in
this age group.
GARV in Children Admitted without Diarrhoea
Of the 620 control specimens, 19 (3.1%; 95% CI 1.9%–
4.7%) tested positive for GARV. This proportion did not vary
by calendar year or by sex. PAGE analysis identiﬁed GARV
RNA in 14 (74%) of the 19 positives. A review of the clinical
records conﬁrmed that none of the GARV-positive controls
gave a history of diarrhoea in the week prior to admission.
The Community Burden of GARV-Associated Diarrhoea
The incidence rates for admission to KDH with diarrhoea
and with GARV-associated diarrhoea are shown in Table 1.
We assume to be negligible the proportion of GARV-positive
children whose diarrhoea was not the result of rotavirus
Figure 2. Flow Diagram Summarising Case and Control Sampling from Childhood Admissions to Kilifi District Hospital, 2002–2004
Percentages within a box refer to the proportion sampled from the preceding box, except where describing the breakdown of reasons why stools were
not collected (entitled ‘‘No stool’’). ‘‘Time limit’’ indicates children who ceased to be eligible because they failed to provide a stool sample within 24
hours of admission. Absence of laboratory results for stool samples collected (*) was due to insufficient sample or mismatch of laboratory and admission
numbers. In total 1,257 children with diarrhoea were not tested (NT) for GARV.
doi:10.1371/journal.pmed.0050153.g002
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infection, and as a consequence make no adjustment to these
incidence ﬁgures to account for potential false-positive
results. Incidence estimates assume that the proportion
GARV positive in cases tested applies to all diarrhoea
admissions whether or not tested. For children under 5 y of
age, the incidence (per 100,000 per annum) of GARV-positive
diarrhoea admissions was estimated at 478. For comparison,
during the same period the incidence rates for admissions of
under-5-y-olds with severe or very severe pneumonia,
bacteraemia, or a ﬁnal diagnosis that included malaria were
2,125, 325, and 2,639, respectively. Variation between
sublocations of the DSS in the incidence of GARV-positive
diarrhoea for children under 5 y is shown in Figure 1. For
residents living near KDH the annual incidence of GARV-
positive diarrhoea admissions in children , 5 y was estimated
at 839 (95% CI 779–901) as opposed to 354 (95% CI 332–377)
for residents from further away.
Severity of Diarrhoea and Concurrent Illness by Rotavirus
Status
The clinical and laboratory features of GARV-positive and
GARV-negative cases are compared in Table 3. Relative to
GARV-negative cases, GARV-positive children presented with
acute nonbloody diarrhoea or vomiting more frequently, and
had a higher prevalence of life-threatening complications at
admission including severe dehydration (sunken eyes), deep
breathing (a correlate of metabolic acidosis), and severely
perturbed biochemical parameters (hypernatraemia, hypo-
kalaemia, severe metabolic acidosis, or elevated creatinine,
but not hyponatraemia), all of which require prompt intra-
venous correction. Compared to the GARV-negative cases,
GARV-positive children had a lower prevalence of concom-
itant illnesses including clinical pneumonia, malnutrition,
and laboratory-conﬁrmed malaria or bacterial infection
(Table 3). The median age of GARV-positive cases (10 mo,
IQR 7–15 mo) was signiﬁcantly lower than that of GARV-
negative cases (14 mo, IQR 9–25 mo) (p, 0.001). ORs for each
feature, adjusted for potential confounding by age, retain the
pattern described above (Table 3). The effect on this analysis
of adjusting for distance from KDH (near versus far) was
negligible and is not included.
Bacterial pathogens were isolated from the blood of 13/588
(2%) GARV-positive cases and 96/1451 (6.6%) GARV-negative
cases (Table 3). Isolates from GARV-positive patients in-
cluded group A b-haemolytic streptococci (2), Staphylococcus
aureus (1), Acinetobacter sp. (5), Pseudomonas sp. (2), Klebsiella sp.
(2), and Salmonella sp. (1). Those from GARV-negative cases
included Streptococcus pneumoniae (22), Escherischia coli (21), and
Salmonella sp. (21), the remainder comprising group A b-
haemolytic streptococci (9), Haemophilus inﬂuenzae (7), Acineto-
bacter sp. (6), S. aureus (5), Pseudomonas sp. (4), Campylobacter sp.
(2), Klebsiella sp. (1), Shigella sp. (1) and a gram-negative coccus
(1). In four GARV-negative cases two species were coinfect-
ing.
Table 1. The Incidence (Per 100,000 Per Year) of Severe Diarrhoea and GARV-Positive Severe Diarrhoea Estimated from Surveillance of
Admissions to Kilifi District Hospital, Kenya 2002–2004
Age Group % Cases
GARV Positive
Resident
Diarrhoea
Admissions
Person-Years of
Observation
Incidence of
Diarrhoea (95% CI)
Incidence of
GARV-Positive Diarrhoeaa
(95% CI)
Infants (,1 y) 38.1 (372/976)b 807 21,529 3,748 (3,494–4,016) 1,431 (1,275–1,600)
Young children (,5 y) 30.0 (587/1,954) 1,706 107,224 1,591 (1,516–1,668) 478 (437–521)
All ages (,13 y) 28.8 (588/2,039) 1,797 253,505 709 (676–742) 204 (187–223)
a % cases GARV positive3 resident diarrhoea admissions/person-years of observation3 100,000. Estimated number of resident GARV cases rounded to nearest integer. Estimates are
unadjusted for the suspected proportion (3%) of GARV positive cases for which the disease is not due to the GARV infection. It is assumed that the prevalence of GARV in diarrhoea cases
not tested in this study is equivalent to that in the cases tested.
bNumber of group A rotavirus–positive samples/total number of specimens tested between 01 January 2002 to 31 December 2004.
doi:10.1371/journal.pmed.0050153.t001
Table 2. Age Distribution of Paediatric Cases of Diarrhoea Tested for GARV and Those Found GARV-Positive from Admissions to KDH,
Kenya between 01 January 2002 and 31 December 2004
Age Group (Years) Diarrhoea Cases Tested GARV Cases Proportion GARV Positive
Within Age Group Out of Total GARV
0–2 84 16 19% 3%
3–5 224 92 41% 16%
6–8 318 130 41% 22%
9–11 350 134 38% 23%
12–17 405 130 32% 22%
18–23 229 50 22% 9%
24–35 219 25 11% 4%
36þ 210 11 5% 2%
Total 2,039 588 29% 100%
doi:10.1371/journal.pmed.0050153.t002
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Mortality and Duration of Hospital Inpatient Stay by GARV
Status
The proportion of GARV-positive cases remaining in
hospital for more than 12 d (3%) was signiﬁcantly lower than
that in GARV-negatives (16%) (Table 3). Mean durations of
hospital stay were 5.2 d and 7.5 d, respectively. In-hospital
mortality in GARV-positive cases was 2%, signiﬁcantly lower
than in GARV-negative cases (9%) (Table 3). Relative to
GARV-negatives, the age-adjusted OR of death in GARV-
positives was 0.21 (95% CI 0.11–0.41; p , 0.001). The
differential in mortality is primarily attributable to the high
prevalence of severe malnutrition amongst the GARV-
negative group compared to GARV-positives (37% versus
14%, p, 0.001, Table 3), and concomitant higher case fatality
in the GARV-negative, compared to GARV-positive, mal-
nourished children (21% versus 6%, p ¼ 0.001). Further
analyses of factors associated with in-hospital mortality in
diarrhoea cases are presented in Table S2 and Text S2.
Four of the GARV-positive children with diarrhoea who
died had malnutrition and one had a lower respiratory tract
infection. The mean annual number of in-hospital deaths
among resident diarrhoea cases under 5 y old was 48, of which
3.6% were GARV positive. Similarly, the annual number of
deaths in resident infant diarrhoea cases was 18, of which
4.9% were GARV positive. These data yield estimated rates
(per 100,000 per year) of hospital deaths attributable to
diarrhoea of 120 (95% CI 100–143) in children under 5 y, and
228 (168–301) in infants, and corresponding estimates of
hospital deaths attributable to GARV-positive diarrhoea of 5
(2–11) and 9 (1–34), respectively (note that these are based on
small numbers of deaths).
Table 3. Clinical, Laboratory, and Outcome Characteristics, Stratified by GARV Status, in Paediatric Diarrhoea Admissions to Kilifi
District Hospital, Kenya 2002 to 2004
Category Feature GARV-Positive
Casesa
(%), n ¼ 588
GARV-Negative
Casesa
(%) n ¼ 1,451
p-Value for Positive
Versus Negativeb
Adjusted OR
(95% CI)c
Gastroenteric history Acute diarrhoea (,14 d) 576 (98) 1,264/1,435 (88) ,0.001 5.38 (2.94–9.82)d
Bloody diarrhoea 20 (3) 118 (8) ,0.001 0.49 (0.30–0.81)e
Vomiting 515 (88) 882 (61) ,0.001 4.10 (3.09–5.35)d
Respiratory Indrawing 90 (15) 277 (19) 0.048 0.65 (0.50–0.86)e
Deep ‘‘acidotic’’ breathing 147 (25) 218 (15) ,0.001 1.53 (1.19–1.96)d
Hypoxia (O2 sat ,90% )
f 11 (2) 55 (4) 0.027 0.54 (0.27–1.7)
Cardiovascular and hydration Decreased skin turgor 191 (32) 406 (28) 0.047 1.07 (0.87–1.34)
Sunken eyes 343 (58) 536 (37) ,0.001 1.99 (1.62–2.44)d
Capillary refill time 3 s 72 (12) 198 (14) 0.428 0.87 (0.65–1.18)
Weak pulse volume 86 (15) 182 (13) 0.219 1.15 (0.86–1.54)
Shockg 210 (36) 496 (34) 0.538 1.07 (0.86–1.31)
Neurological Lethargy 120 (20) 197 (14) ,0.001 1.60 (1.23–2.08)d
Prostration or coma 19 (3) 67 (5) 0.181 0.87 (0.50–1.50)
Laboratory Acidosis (base deficit .15 mmol/l) 248/541 (46) 226/1,298 (17) ,0.001 3.41 (2.69–4.32)d
Hypernatraemia (.145 mmol/l) 34/494 (7) 19/1,140 (2) ,0.001 3.53 (1.93–6.46)d
Hyponatraemia (,125 mmol/l) 14/494 (3) 84/1,140 (7) ,0.001 0.42 (0.23–0.76)e
Hypokalaemia (,3 mmol/l) 221/494 (45) 376/1,141 (33) ,0.001 1.53 (1.22–1.92)d
Elevated creatinine (.80 lmol/l)h 87/482 (18) 156/1,116 (14) 0.040 2.29 (1.66–3.18)d
Hypoglycaemia (,2.5 mmol/l) 11/548 (2) 60/1,321 (5) 0.008 0.86 (0.43–1.71)
Leucocytosis (WBC .12 3 109/l)i 210/575 (37) 711/1,420 (50) ,0.001 0.60 (0.48–0.74)e
Coexisting illness Severe pneumoniaj 54 (9) 205 (14) 0.002 0.51 (0.36–0.70)e
Very severe pneumoniak 16 (3) 71 (5) 0.029 0.54 (0.31–0.96)e
Malnutritionl 82 (14) 537 (37) ,0.001 0.35 (0.27–0.46)e
Severe anaemia (Hb ,5 g/dl) 6/575 (1) 89/1,420 (6) ,0.001 0.18 (0.08–0.41)e
Malaria parasitaemia 65 (11) 386 (27) ,0.001 0.38 (0.28–0.51)e
Bacteraemia (blood culture positive) 13 (2) 96 (7) ,0.001 0.37 (0.20–0.68)e
Outcome Death 10 (2) 132 (9) ,0.001 0.23 (0.12–0.45)e
Inpatient duration .12 d 20 (3) 229 (16) ,0.001 0.26 (0.16–0.41)e,m
aNumber with characteristic and percentage (%) presented; denominator is n unless otherwise specified in column.
bComparison of GARV-positive and -negative proportions, with probability p-value of Fisher exact test.
cOdds of feature in GARV-positive divided by odds in GARV-negative cases, adjusted for age class.
dSignificant positive association.
eSignificant negative association.
fOxygen saturation measured by pulse oxymeter (Nelcor).
gTemperature gradient, capillary refill . 3 s, or weak pulse volume.
hCreatinine . 110 lmol/l if age , 12 mo.
iWBC . 153 109/l if age , 12 mo.
jHistory of acute cough or difficulty in breathing, and subcostal recession.
kHistory of acute cough or difficulty in breathing, and impaired consciousness or hypoxia.
lSmall MUAC for age, bipedal oedema or visible severe wasting. Small MUAC was defined as  10th percentile calculated for all KDH admissions 2002–2004 generating the following cut-
off values by age: 0–5 mo  7.7 cm, 6–23 mo  11.0 cm, 24–35 mo  11.6 cm, 36–59 mo  12.2 cm,  60 mo  12.8 cm (for comparable age classes these show close similarity to those
previously defined [20]).
mAdjusted for age class and discharge status.
doi:10.1371/journal.pmed.0050153.t003
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Discussion
In our study, conducted in a rural district hospital in Kenya
over a 3-y period, GARV was identiﬁed in 29% of children
admitted with diarrhoea. The prevalence was highest in the
youngest children: 38% in those , 1 y of age and 30% in
under-5-y-olds. We estimated the annual incidence (per
100,000 population) of GARV-associated hospitalisations with
acute severe diarrhoea at 1,275–1,600 in children under 1 y of
age, 437–521 in children under 5 y, and 187–223 in those
under 13 y, similar ﬁgures to those reported in industrialised
nations with greater access to health care and diagnostic
facilities [1]. Our data suggest that in the area served by our
hospital, over 1% of infants are hospitalised with severe
GARV-associated diarrhoea each year. By 5 y of age, over 2%
of children will have been hospitalised with GARV diarrhoea
(Table 1); by extrapolation, therefore, given the under-5-y
population of Kenya (5.98 million in 2005 [25]), in the nation
as a whole an effective rotavirus vaccine could prevent in
excess of 28,000 hospital admissions in this age group every
year. Our incidence estimates include only the children who
present to hospital with diarrhoea; the under-ascertainment
implicit in this method is reﬂected by the fact that the
estimated incidence was over 70% higher for the population
immediately served by KDH than for the DSS as a whole. It is
likely that our current study represents a conservative
estimate of the true burden of rotavirus disease.
External validity of these data is an important consid-
eration in making extrapolations. KDH paediatric care is
unusually well resourced for a Kenyan district hospital.
However, apart from mortality and in-patient stay, the
characteristics of the study participants (detailed in Table 3)
are determined at admission, and uninﬂuenced by in-patient
management. Furthermore, there is no evidence that local
knowledge of the high quality care at KDH inﬂuences
admission rates. At the time of this study demographic and
health indicators for Kiliﬁ District were not dissimilar to
much of Kenya [26].
Only a small proportion (3%) of children without
diarrhoea (controls) were found to be GARV positive. This
provides assurance that the vast majority of the observed
GARV-associated severe diarrhoea is potentially GARV-
vaccine preventable. Few studies have investigated the
prevalence of rotavirus shedding in the absence of disease
[27], and yet asymptomatic rotavirus infection [27–29] and
prolonged excretion have both been reported in children
[27,30,31], in particular in neonates. It is of interest that ﬁve
of 19 positive controls in this study were less than 2 wk old,
because subclinical infection and associated prolonged virus
shedding, particularly within young infants, may play an
important role in the spread of GARV infection. Consistent
with previous studies [8] we found that the major burden
(85%) of GARV diarrhoea fell on children under 18 mo of
age, and over 60% of cases were in infants. Of importance to
the delivery of a vaccine within the current immunization
schedule, the proportion of cases in children under 3 mo old
was only 3% and in those under 6 mo was 18%.
From the clinical perspective, we found that relative to
GARV-negative cases, the GARV-positive children with
diarrhoea were more ill on admission, but their clinical signs
and symptoms were mainly reﬂections of ﬂuid loss and
electrolyte imbalance and, therefore, readily corrected with
the good supportive care available at this hospital. The
GARV-negative children admitted with diarrhoea were less
acutely unwell at admission but had a higher incidence of
coexisting illnesses, such as malnutrition, that were less
readily treated and consequently had worse outcomes.
Compared with early work in the US [32] we identify a
similar clinical picture of higher prevalence of dehydration
and vomiting, and short in-hospital stay, in rotavirus-infected
relative to uninfected children, with similar age distribution
of children with GARV infection but of lower prevalence.
However, our ﬁndings of a marked differential in the degree
of acidosis and electrolyte imbalance between the two groups
were not previously identiﬁed. While we consider it unlikely
that there was a substantial systematic bias in the distribution
of severity characteristics (Table 3) attributable to the group
of diarrhoea patients admitted who were not tested for
GARV, or to patterns of admission related to distance, these
are uncertainties that urge caution in the interpretation of
the data.
A limitation with the present study is the bias inevitable
with hospital-based surveillance in estimating community
incidence of GARV severe diarrhoea and associated mortal-
ity. Such estimates are rooted in parental interpretation of
what constitutes disease severe enough to warrant hospital
attendance. Clearly, this will be linked to factors related to
health care utilisation such as ease of access. Possible
distortion of the distribution of severity in relation to
distance, for example, resulting from children arriving from
greater distances representing the more severe cases within
their home areas, could lead to overestimation of GARV-
positive diarrhoea severity relative to GARV-negative diar-
rhoea. A further limitation results from the failure to test
around one-third of eligible children, and although its effect
on the proﬁle of GARV severe disease presented must be
considered uncertain, we present some evidence that suggests
it is not substantial.
Despite its importance in deﬁning the need for rotavirus
vaccines, data on GARV-associated mortality from develop-
ing countries are limited [33]. The low mortality reported for
cases in the current study may well reﬂect the fact that these
children were ostensibly healthy individuals, and the acute
life-threatening metabolic derangements we commonly re-
corded were readily reversed in the well-functioning setting
of KDH. In the majority of African hospitals, which do not
provide immediate ﬂuid and electrolyte resuscitation, it
seems likely that mortality from GARV would be very much
higher.
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Figure S1. GARV-Positive Diarrhoea Admissions to Kiliﬁ District
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Shown are monthly cases of diarrhoea (solid line), tests for GARV
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diamonds), and relative humidity (closed triangles). Climate data
was obtained from the national meteorological station Kiliﬁ Institute
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Table S1. Characteristics of Patients with Diarrhoea Who Were
Tested or Not Tested (NT) for GARV, for Children with a Final
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Found at doi:10.1371/journal.pmed.0050153.st001 (49 KB DOC).
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Editors’ Summary
Background. Rotavirus is a leading global cause of diarrhea in babies
and young children. Indeed, most children become infected at least once
with this virus before their fifth birthday. Rotavirus is usually spread by
children or their caregivers failing to wash their hands properly after
going to the toilet and then contaminating food or drink. The symptoms
of rotavirus infection—diarrhea, vomiting, and fever—are usually mild,
but if the diarrhea is severe it can quickly lead to dehydration. Mild to
moderate dehydration can be treated at home by providing the patient
with plenty of fluids or with a special rehydration drink that replaces lost
water and salts. However, for infants or toddlers who become severely
dehydrated, rehydration with intravenous fluids (fluids injected directly
into a vein) in hospital may be essential. Unfortunately, in developing
countries in sub-Saharan Africa and elsewhere, this treatment is not
widely available and every year more than half a million young children
die from rotavirus infections.
Why Was This Study Done? Two rotavirus vaccines that could reduce
this burden of disease are currently undergoing clinical trials to
determine their effectiveness in sub-Saharan Africa. However, very little
is known about the incidence of severe rotavirus infections among
children living in this region (that is, how many children develop severe
disease every year) or about the clinical characteristics of the disease
here. Public-health officials need this baseline information before they
can make informed decisions about the mass introduction of rotavirus
vaccination and to help them judge whether the intervention has been
successful if it is introduced. In this study, the researchers examine the
incidence and clinical characteristics of rotavirus infections (specifically,
group A rotavirus [GARV] infections; there are several different
rotaviruses but GARV causes most human infections) among children
admitted to the district hospital in Kilifi, Kenya.
What Did the Researchers Do and Find? During the 3-year study, more
than 15,000 children under the age of 13 years were admitted to Kilifi
District Hospital, a little under a quarter of whom had severe diarrhea.
Nearly a third of the patients admitted with diarrhea who were tested
had a GARV-specific protein in their stools (faeces); by contrast, only
three in 100 children admitted without diarrhea showed any evidence of
GARV infection. Two-thirds of the GARV-positive children were infants
(under 1 year old). Using these figures and health surveillance data
(records of births, deaths, and causes of death) collected in the area
around the hospital, the researchers calculated that the annual incidence
(per 100,000 children) of GARV-positive hospital admissions in the region
was 1,431 for infants and 478 for children under age 5 years. Children
with GARV-positive diarrhea were less likely to have other illnesses (for
example, malnutrition) than those admitted with GARV-negative
diarrhea, the researchers report, but were more likely to have life-
threatening complications such as severe dehydration and salt
imbalances in their blood. However, despite being more ill on admission,
only 1 in 50 children with GARV-positive diarrhea died, compared to
nearly 1 in 10 of the children with GARV-negative diarrhea; the GARV-
positive children also left hospital quicker than those who were GARV-
negative.
What Do These Findings Mean? These findings indicate that severe
GARV-positive diarrhea is a major cause of hospital admission among
otherwise healthy young children in the Kilifi region of Kenya. By the
time they are 5 years old, the researchers estimate that 1 in 50 of the
children living in this region will have been admitted to hospital with
severe GARV-positive diarrhea. Because rotavirus vaccines prevent
virtually all severe rotavirus-associated disease (at least in developed
countries where their effectiveness has been extensively tested), the
researchers estimate that vaccination might prevent more than 28,000
hospitalizations annually across Kenya; however, this prediction assumes
that it is valid to extrapolate from the data obtained from this one district
hospital to the entire country.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0050153.
 The US Centers for Disease Control and Prevention provides
information about rotavirus infections, surveillance, and vaccination
(in English and Spanish)
 The UK National Health Service Direct health encyclopedia provides
information on rotavirus infections
 MedlinePlus also provides links to information on rotavirus (in English
and Spanish)
 The African Rotavirus Surveillance Network is working to improve
knowledge about rotavirus infections in Africa
 The Rotavirus Vaccine Program aims to reduce child illness and death
from diarrhea by increasing the availability of rotavirus vaccines in
developing countries (in English and Spanish)
 PATH, a nonprofit international organization that aims to create
sustainable, culturally relevant solutions to global health problems,
also provides detailed information on rotavirus surveillance and
disease burden
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